Search - tctmd.com

Displaying 141 - 160 of 237

Sort: Relevancy | Date

Presentation TCT 2014

Definitely To Prevent Stent Thrombosis and MI!

Presenter: Gregg W. Stone

September 15, 2014

Presentation TCT 2014

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux

September 15, 2014

Presentation TCT 2014

Use of OCT to Evaluate Stent Failures (Thrombosis and Restenosis)

Presenter: Robert S. Schwartz, Ron Waksman, Jorge F. Saucedo, Evelyn S. Regar

September 14, 2014

Presentation TCT 2014

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

Use of IVUS to Evaluate Stent Failures (Thrombosis and Restenosis)

Presenter: Robert S. Schwartz, Ron Waksman, Jorge F. Saucedo, Gary S. Mintz

September 14, 2014

Presentation TCT 2014

Case Study: Recurrent Stent Thrombosis

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Tullio Palmerini

September 14, 2014

Presentation TCT 2014

Hematologic Etiologies of Stent Thrombosis and How to Evaluate

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Giulio G. Stefanini

September 14, 2014

Presentation TCT 2014

Evaluation and Treatment of Stent Thrombosis: From Acute Patency to Long-term Vascular Stability

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Ron Waksman

September 14, 2014

Presentation TCT 2014

TCT 642: Stent Thrombosis Rates with an Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus a Durable Polymer, Everolimus-Eluting Stent in Patients Undergoing Percutaneous Coronary Intervention: 3-Year Follow-up from the COMPARE II Trial

Presenter: Pieter C. Smits

September 14, 2014

Presentation TCT 2014

TCT 643: Very Late Stent Thrombosis After Revascularization with the Biolimus-Eluting, Biodegradable Polymer-Coated Nobori Stent Versus Durable Polymer-Coated, Sirolimus-Eluting Stents from the SORT-OUT V Trial

Presenter: Evald H. Christiansen

September 14, 2014

Presentation TCT 2014

Follow the Data: Fluorinated Polymer-Based DES are Safer than Bioresorbable-Based DES!

Presenter: Hyo-Soo Kim

September 14, 2014

Presentation TCT 2014

Bioresorbable Polymer-Based DES are the Right Choice to Minimize Stent Thrombosis!

Presenter: Stephan Windecker

September 14, 2014

Presentation TCT 2014

Are Current DES Really Safer Than BMS?

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Tullio Palmerini

September 14, 2014

Presentation TCT 2014

Beyond the Guidelines: What Is the Optimal Duration of DAPT After Metallic DES Implantation, and Is It Device Specific?

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Marco Valgimigli

September 14, 2014

Presentation TCT 2014

Prevention of Stent Thrombosis: Devices, Pharmacology, Technique, Patients, and More

Presenter: Stephen G. Ellis, Patrick W. Serruys, Elvin Kedhi, Lorenz Raber

September 14, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

Complication Case #2: Stent Thrombosis and Abrupt Closure

Presenter: Run-Lin Gao, Martin B. Leon, Gregg W. Stone, Qi Zhang

September 13, 2014

Presentation TCT 2014

Restenosis and Stent Thrombosis

Presenter: George D. Dangas, Kevin J. Croce

September 13, 2014

Presentation TCT 2014

HORIZONS-AMI and EUROMAX Stent Thrombosis: Predictors of Stent Thrombosis and Risk for 30-Day Mortality After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

Presenter: Patrick W. Serruys, George D. Dangas

September 13, 2014

Presentation TCT 2014

TCT 644: Stent Thrombosis Rates of the Biodegradable Polymer, Biolimus-Eluting Stent Versus the Durable Polymer, Everolimus-Eluting Stent in All Comers Undergoing PCI: A Pooled Analysis of the COMPARE II and NEXT Trials at 1 Year

Presenter: Valentin Fuster, Pieter C. Smits

September 13, 2014

Advertisement

Definitely To Prevent Stent Thrombosis and MI!

Cangrelor III: Detailed Effects on Intraprocedural and Postprocedural Stent Thrombosis

Use of OCT to Evaluate Stent Failures (Thrombosis and Restenosis)

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Use of IVUS to Evaluate Stent Failures (Thrombosis and Restenosis)

Case Study: Recurrent Stent Thrombosis

Hematologic Etiologies of Stent Thrombosis and How to Evaluate

Evaluation and Treatment of Stent Thrombosis: From Acute Patency to Long-term Vascular Stability

TCT 642: Stent Thrombosis Rates with an Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus a Durable Polymer, Everolimus-Eluting Stent in Patients Undergoing Percutaneous Coronary Intervention: 3-Year Follow-up from the COMPARE II Trial

TCT 643: Very Late Stent Thrombosis After Revascularization with the Biolimus-Eluting, Biodegradable Polymer-Coated Nobori Stent Versus Durable Polymer-Coated, Sirolimus-Eluting Stents from the SORT-OUT V Trial

Follow the Data: Fluorinated Polymer-Based DES are Safer than Bioresorbable-Based DES!

Bioresorbable Polymer-Based DES are the Right Choice to Minimize Stent Thrombosis!

Are Current DES Really Safer Than BMS?

Beyond the Guidelines: What Is the Optimal Duration of DAPT After Metallic DES Implantation, and Is It Device Specific?

Prevention of Stent Thrombosis: Devices, Pharmacology, Technique, Patients, and More

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Complication Case #2: Stent Thrombosis and Abrupt Closure

Restenosis and Stent Thrombosis

HORIZONS-AMI and EUROMAX Stent Thrombosis: Predictors of Stent Thrombosis and Risk for 30-Day Mortality After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

TCT 644: Stent Thrombosis Rates of the Biodegradable Polymer, Biolimus-Eluting Stent Versus the Durable Polymer, Everolimus-Eluting Stent in All Comers Undergoing PCI: A Pooled Analysis of the COMPARE II and NEXT Trials at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content